Combinations of monoclonal antibodies (mAbs) against different epitopes on the same
antigen synergistically neutralize many viruses. However, there are limited studies …

Antibodies against the central repeat of the Plasmodium falciparum (Pf) circumsporozoite
protein (CSP) inhibit parasite activity and correlate with protection from malaria. However …

Plasmodium falciparum malaria contributes to a significant global disease burden.
Circumsporozoite protein (CSP), the most abundant sporozoite stage antigen, is a prime …

Potent and durable vaccine responses will be required for control of malaria caused by
Plasmodium falciparum (Pf). RTS, S/AS01 is the first, and to date, the only vaccine that has …

Immunization with attenuated Plasmodium falciparum sporozoites (PfSPZs) has been shown
to be protective against malaria, but the features of the antibody response induced by this …

Abstract Development of a highly effective vaccine or antibodies for the prevention and
ultimately elimination of malaria is urgently needed. Here we report the isolation of a number …

Circumsporozoite protein (CSP) of Plasmodium falciparum is a protective human malaria
vaccine candidate. There is an urgent need for models that can rapidly down-select novel …

The induction of protective humoral immune responses against sporozoite surface proteins
of the human parasite Plasmodium falciparum (Pf) is a prime goal in the development of a …

Lasting protection has long been a goal for malaria vaccines. The major surface antigen on
Plasmodium falciparum sporozoites, the circumsporozoite protein (PfCSP), has been an …

Human monoclonal antibodies (mAbs) against the central repeat and junction domain of
Plasmodium falciparum circumsporozoite protein (PfCSP) have been studied extensively to …